查詢結果分析
相關文獻
- 以多頻道心室功能攝影監測乳癌病人接受化療藥物對於左心室射出分率之影響
- 化學治療引起心毒性
- 轉移性乳癌的化學治療
- 一位乳癌患者接受乳房切除與化學治療的護理經驗
- 乳癌的化學治療
- 轉移性乳癌化學治療之新利器--微脂體包覆化學藥物Liposomal Doxorubicin
- 乳癌病人用藥依從性及相關因素之研究
- Fatigue and Related Factors in Women with Breast Cancer Receiving Chemotherapy
- Factors Related to Quality of Life in Breast Cancer Patients Receiving Chemotherapy
- MVP (Mitomycin-C, Vinblastine, Cisplatin) Salvage Chemotherapy for Relapsed and Refractory Metastatic Breast Cancer
頁籤選單縮合
題名 | 以多頻道心室功能攝影監測乳癌病人接受化療藥物對於左心室射出分率之影響=Multigated Blood Pool Analysis to Examine the Effect of Chemotherapy on Left Ventricular Ejection Fraction |
---|---|
作者 | 林昰璁; 林俊宏; 莊紫翎; 楊絢如; 劉芳馨; | 書刊名 | Annals of Nuclear Medicine and Molecular Imaging |
卷期 | 36:3 2023.09[民112.09] |
頁次 | 頁93-101 |
分類號 | 416.2352 |
關鍵詞 | 乳癌; 心毒性; 化學治療; 左心室射出分率; 多頻道心室功能攝影; Breast cancer; Cardiotoxicity; Chemotherapy; Left ventricular ejection fraction; Multigated blood pool analysis; |
語文 | 中文(Chinese) |
DOI | 10.6332/ANMMI.202309_36(3).0002 |
中文摘要 | 背景:本篇利用多頻道心室功能攝影(multigated blood pool analysis, MUGA)追蹤乳癌病人接受化學治療前、後左心室射出分率(left ventricular ejection fraction, LVEF)之變化。方法:本研究共納入56位乳癌病患來追蹤化療藥物對於心臟之心毒性影響,分別在開始化療前及化療開始後第3、6及12個月以MUGA檢查,評估不同時間點LVEF的變化,之後將4次檢查的LVEF利用統計軟體,使用Friedman檢定分析與Wilcoxon符號等級檢定進行事後比較,以baseline為基準比較化療前後差異,評估LVEF在使用化療藥物前後的變化。結果:經由統計結果得出在化療前baseline的LVEF為66.50±8.95%,在第3個月的檢查結果LVEF為64.73±7.15%,第6個月時為63.84±6.95%,第12個月的LVEF為65.71±7.98%,在Friedman檢定分析得知化療前後LVEF有顯著性差異(p=0.011),接著再進一步使用Wilcoxon符號等級檢定進行事後比較,得出在化療開始後第6個月與baseline之間有顯著性差異(p=0.001),顯示出使用化療藥物後因LVEF變異,而造成LVEF暫時下降。討論:乳癌治療所使用的化療藥物,可能影響LVEF。MUGA可用於評估化學治療後因為心臟功能變異而造成的LVEF降低,提供臨床使用化學治療藥物時重要的參考指標。 |
英文摘要 | Background: This study utilized multigated blood pool analysis (MUGA) to monitor changes in left ventricular ejection fraction (LVEF) before and after chemotherapy in breast cancer patients. Methods: A total of 56 breast cancer patients were included in this study to track the cardiac function after receiving chemotherapy in breast cancer patients. MUGA was utilized to evaluate the changes of LVEF before chemotherapy, and 3, 6, and 12 months after receiving chemotherapy. The LVEF changes across different time points of cardiac function assessment were analyzed by Friedman two-way analysis of variance by ranks and Wilcoxon signed-rank test. Results: The baseline LVEF before chemotherapy was 66.50 ± 8.95%, the LVEF at 3 months was 64.73 ± 7.15%, 63.84 ± 6.95% at 6 months, and 65.71 ± 7.98% at 12 months. Overall, there was significant difference in LVEF variations across different time points of cardiac function assessment (p = 0.011); however, significant differences in cardiac function variation were observed between the 6th month after receiving chemotherapy and baseline (p = 0.001). Temporary decline in LVEF at 6 months after receiving chemotherapy was noted. Conclusions: Our study revealed that breast cancer patients had a significant decline in LVEF at 6 month after receiving chemotherapy, suggesting the importance of monitoring cardiac function at this specific time interval during treatment. MUGA can be utilized to assess the LVEF variation and provide a crucial reference indicator for assessing cardiac function during breast cancer treatment. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。